No connection

Search Results

RLYB

BEARISH
$8.22 Live
Rallybio Corporation · NASDAQ
$1.96 52W Range $11.49

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 19, 2026
Market cap
$43.48M
P/E
N/A
ROE
-15.0%
Profit margin
N/A
Debt/Equity
0.0
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
RLYB exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 0/9, indicating a complete lack of financial health across profitability and efficiency metrics. While the company maintains a strong liquidity position with a Current Ratio of 14.51 and zero debt, its operating margin of -2888.29% and a Price/Sales ratio of 50.68 suggest an unsustainable burn rate and extreme overvaluation relative to current revenue. The recent 1-year price surge appears speculative, as it is decoupled from the deterministic health scores and a bearish technical trend of 0/100.

Key Strengths

Exceptional short-term liquidity (Current Ratio: 14.51)
Zero debt (Debt/Equity: 0.00)
Explosive year-over-year revenue growth (484.20%)
Trading below book value (Price/Book: 0.75)
Recent history of beating earnings estimates (2/4 last quarters)

Key Risks

Severe operational inefficiency (Operating Margin: -2888.29%)
Critical failure in deterministic health (Piotroski F-Score: 0/9)
Extreme valuation premium on sales (P/S: 50.68)
Consistent negative earnings and high cash burn
Bearish technical trend and weak insider sentiment (40/100)

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
22
Weak
Value
20
Future
45
Past
30
Health
15
Dividend
0
AI Verdict
Speculative/High Risk
Key drivers: Piotroski F-Score of 0/9, Extreme P/S ratio, High cash runway vs. severe operating losses
Confidence
90%
Value
20/100

Stock is cheap relative to assets but prohibitively expensive relative to revenue.

Positives
  • P/B ratio of 0.75
Watchpoints
  • P/S ratio of 50.68
  • No Graham Number due to lack of earnings
Future
45/100

Growth is present in revenue but not translating to bottom-line viability.

Positives
  • High YoY revenue growth (484%)
Watchpoints
  • Negative EPS progression
  • High burn rate
Past
30/100

Long-term value destruction despite recent speculative volatility.

Positives
  • Strong 1-year price recovery (+311%)
Watchpoints
  • Devastating 5-year return (-92.7%)
  • Consistent quarterly losses
Health
15/100

Balance sheet is liquid, but the business model is fundamentally unhealthy.

Positives
  • Zero debt
  • High current ratio
Watchpoints
  • Piotroski F-Score: 0/9
  • Negative ROE and ROA
Dividend
0/100

Non-dividend paying growth/biotech entity.

Positives
No standout positives identified.
Watchpoints
  • No dividend payments
  • 0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$8.22

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for RLYB and closest competitors.

Updated 2026-04-17
RLY
Rallybio Corporation
Primary
5Y
-92.7%
3Y
-76.3%
1Y
+311.0%
6M
+92.1%
1M
-12.2%
1W
-2.6%
ARA
Accuray Incorporated
Peer
5Y
-93.2%
3Y
-87.0%
1Y
-78.7%
6M
-76.4%
1M
-27.4%
1W
-24.4%
APL
Apollomics, Inc.
Peer
5Y
-98.0%
3Y
-98.1%
1Y
+148.8%
6M
+191.4%
1M
-0.5%
1W
-0.8%
RNX
RenovoRx, Inc.
Peer
5Y
-86.2%
3Y
-68.2%
1Y
-2.0%
6M
-10.7%
1M
-2.9%
1W
+1.5%
INC
InterCure Ltd.
Peer
5Y
-91.7%
3Y
-67.4%
1Y
-37.5%
6M
-52.3%
1M
-4.7%
1W
+0.4%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-1.52
PEG Ratio
N/A
P/B Ratio
0.75
P/S Ratio
50.68
EV/Revenue
-12.91
EV/EBITDA
0.35
Market Cap
$43.48M

Profitability

Profit margins and return metrics

Profit Margin N/A
Operating Margin -2888.29%
Gross Margin N/A
ROE -15.01%
ROA -30.07%

Growth

Revenue and earnings growth rates

Revenue Growth +484.2%
Earnings Growth N/A
Q/Q Revenue Growth +484.21%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.0
Low debt
Current Ratio
14.51
Strong
Quick Ratio
12.96
Excellent
Cash/Share
$10.35

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Op. Margin
-2888.3%
Net Margin
-2636.0%
Total Assets
$0.1B
Liabilities
$0.0B
Equity
$0.1B
Debt/Equity
0.07x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-03-16
$-1.52
-22.6% surprise
2025-11-06
$2.88
+284.6% surprise
2025-08-07
$N/A
2025-08-07
$-1.76
+10.2% surprise

Healthcare Sector Comparison

Comparing RLYB against 437 companies in the Healthcare sector (26 bullish, 137 neutral, 274 bearish)
Return on Equity (ROE)
-15.01%
This Stock
vs
-98.3%
Sector Avg
-84.7% (Below Avg)
Debt to Equity
0.0
This Stock
vs
3.11
Sector Avg
-99.9% (Less Debt)
Revenue Growth
484.2%
This Stock
vs
124.48%
Sector Avg
+289.0% (Fast Growth)
Current Ratio
14.51
This Stock
vs
4.65
Sector Avg
+212.1% (Stronger)

Similar Companies

Peer comparison within the same industry

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
8-K
2026-03-31
10-K
10-K
2026-03-16

RLYB filed its annual 10-K on March 16, 2026, which includes sections on business operations, risk factors, and management's discussion and analysis. Specific financial highlights and risk details were not provided in the available excerpts.

8-K
8-K
2026-03-02
8-K
8-K
2026-01-29

Relay Therapeutics reported its fourth-quarter and full-year financial results for the fiscal year ended December 31, 2025.

DEF 14A
DEF 14A
2026-01-02

RLYB filed a definitive proxy statement (DEF 14A) on January 2, 2026, to provide shareholders with information regarding matters to be voted on at an upcoming meeting.

10-Q
10-Q
2025-11-06

RLYB filed its 10-Q on November 6, 2025. While specific financial highlights were not provided in the excerpt, the filing identifies 36 risk factors under Item 1A.

8-K
8-K
2025-11-06
8-K
8-K
2025-08-29
10-Q
10-Q
2025-08-07

RLYB filed its quarterly 10-Q report on August 7, 2025. The filing includes a section on Risk Factors under Item 1A, although specific financial highlights and detailed risk descriptions were not provided in the available excerpt.

8-K
8-K
2025-08-07
8-K
8-K
2025-07-08
8-K
8-K
2025-06-27
8-K
8-K
2025-05-16
10-Q
10-Q
2025-05-08
8-K
8-K
2025-05-08
Data sourced from SEC EDGAR. AI summaries generated automatically.

Past News Coverage

Recent headlines mentioning RLYB from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile